{"altmetric_id":807131,"counts":{"readers":{"mendeley":9,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["IJGConline"],"posts_count":1}},"citation":{"abstract":"Pegylated liposomal doxorubicin (PLD) is an established treatment for relapsed ovarian cancer. Preclinical and clinical evidences in other tumor types suggest that the proteasome inhibitor bortezomib can act synergistically with PLD.","abstract_source":"pubmed","altmetric_jid":"4f6fa61d3cf058f6100078c8","doi":"10.1097\/igc.0b013e318251051a","first_seen_on":"2012-06-24T23:22:58+00:00","issns":["1048-891X"],"issue":"5","journal":"International Journal of Gynecological Cancer","last_mentioned_on":1340579650,"links":["http:\/\/journals.lww.com\/ijgc\/Abstract\/2012\/06000\/An_Open_Label_Phase_2_Study_of_Twice_Weekly.14.aspx"],"pdf_url":"http:\/\/pdfs.journals.lww.com\/ijgc\/2012\/06000\/An_Open_Label_Phase_2_Study_of_Twice_Weekly.14.pdf","pmid":"22635029","pubdate":"2012-06-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"792","subjects":["neoplasms","gynecology"],"title":"An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens","type":"article","volume":"22","mendeley_url":"http:\/\/www.mendeley.com\/research\/openlabel-phase-2-study-twiceweekly-bortezomib-intermittent-pegylated-liposomal-doxorubicin-patients"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":5041086,"mean":5.964734720803,"rank":4211030,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":5041086,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":77968,"mean":5.294467531135,"rank":64605,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":77968,"percentile":1},"this_journal":{"total_number_of_other_articles":1474,"mean":0.92649422946368,"rank":699,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1474,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":69,"mean":0.56455882352941,"rank":26,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":69,"percentile":1}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Professor > Associate Professor":1,"Student  > Doctoral Student":1,"Researcher":1,"Student  > Ph. D. Student":1,"Student  > Postgraduate":2,"Student  > Master":2,"Student  > Bachelor":1},"by_discipline":{"Medicine and Dentistry":4,"Agricultural and Biological Sciences":2,"Nursing and Health Professions":1,"Biochemistry, Genetics and Molecular Biology":1,"Environmental Science":1}}},"geo":{"mendeley":{"GB":1,"ES":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/#!\/IJGConline\/status\/217032898765783040","citation_ids":[807131],"posted_on":"2012-06-24T23:14:10+00:00","author":{"name":"IJGC","url":"http:\/\/ijgc.net","image":"https:\/\/pbs.twimg.com\/profile_images\/756209106717777920\/fvbA4WtA_normal.jpg","description":"IJGC is the primary publication for detection, prevention, diagnosis, and treatment of gynecologic malignancies. Emphasizes a multidisciplinary approach.","id_on_source":"IJGConline","tweeter_id":"174787278","geo":{"lt":null,"ln":null},"followers":197},"tweet_id":"217032898765783040"}]}}